{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-004713","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2021-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.927377+00:00","generated_at":"2026-06-28T07:35:22.773679+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Sarepta appoints Stephen Mayo to board, promotes Rodino-Klapac to R&D head, O'Neill departs","bullets":["Stephen L. Mayo appointed to Sarepta board, effective Nov 16, 2021; receives $712,500 equity grant split between RSUs and options plus $50k annual cash.","Louise Rodino-Klapac promoted to Head of R&D, Chief Scientific Officer; granted 40,000 RSUs vesting 25% annually over 4 years.","Gilmore O'Neill mutually agreed to end employment effective Nov 30, 2021; will serve as consultant through Q1 2022.","Outstanding equity awards issued to O'Neill continue to vest during the consulting period."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-004713","json":"https://secwatch.observer/filing/0000950170-21-004713.json","markdown":"https://secwatch.observer/filing/0000950170-21-004713.md","text":"https://secwatch.observer/filing/0000950170-21-004713.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000095017021004713/0000950170-21-004713-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000095017021004713/srpt-20211115.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T07:35:22.773679+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3277c2925d","claim":"Gilmore O'Neill resigned as other_named_officer at Sarepta Therapeutics, Inc..","evidence_excerpt":"On November 15, 2021, the Company and Gilmore O’Neill, M.B., M.M.Sc. mutually agreed to end Dr. O'Neill's employment with the Company, effective as of November 30, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/873303/000095017021004713/0000950170-21-004713-index.htm","confidence":0.7,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"77c4581090","claim":"Stephen L. Mayo was appointed as Director at Sarepta Therapeutics, Inc..","evidence_excerpt":"On November 16, 2021, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the \"Company\") appointed Stephen L. Mayo, Ph.D. as a director of the Company, effective as of November 16, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/873303/000095017021004713/0000950170-21-004713-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9c9488da15","claim":"Louise Rodino-Klapac changed role as Head of R&D, Chief Scientific Officer at Sarepta Therapeutics, Inc..","evidence_excerpt":"On November 16, 2021, Louise Rodino-Klapac, Ph.D., the Company's Chief Scientific Officer, was promoted to Head of R&D, Chief Scientific Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/873303/000095017021004713/0000950170-21-004713-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Head of R&D, Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}